A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) as Monotherapy in Patients With Neuromyelitis Optica (NMO) and...

Abstract

EudraCT Number: 2015-005431-41
Sponsor Protocol Number: BN40900(SA-309JG)
Sponsor Name: F. Hoffmann-La Roche Ltd.
Start Date: 2017-10-16
Medical condition: Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD)
Disease:
Version: 20.0
SOC Term: 100000004852
Classification Code: 10029322
Term: Neuromyelitis optica
Level: LLT

Population Age: Adults, Elderly
Gender: Male, Female
Trial Protocol: PL (Completed), HR (Completed)